3 recruiting, 2 withdrawn, 1 active not recruiting, 1 completed. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 2, Withdrawn 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 6 | Recruiting 3, Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow bexmarilimab: new trials by email Literature Review of bexmarilimab trials Research Report on bexmarilimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes bexmarilimab (1mg/kg), azacitidine, Placebo - Higher Risk Myelodysplastic Syndromes | Phase 2 | Recruiting | Faron Pharmaceuticals Ltd | 90 | 2026-10-01 | 2026-10-20 |
| Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose - Melanoma (Skin Cancer), Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 62 | 2026-08-28 | 2026-09-08 |
| A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma. bexmarilimab, Doxorubicin - Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Recruiting | MedSIR | 278 | 2026-08-20 | 2026-08-31 |
| Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer bexmarilimab (FP-1305), Pembrolizumab - Non-small Cell Lung Cancer | Phase 1 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2023-06-01 | 2023-07-20 | |
| A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies Bexmarilimab, Azacitidine, Venetoclax - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Faron Pharmaceuticals Ltd | 181 | 2022-06-02 | 2026-04-23 |
| A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma bexmarilimab - Carcinoma, Renal Cell, Carcinoma Colon | Phase 1 / Phase 2 | Withdrawn | Faron Pharmaceuticals Ltd | 2021-10-07 | 2022-05-11 | |
| A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) FP-1305 (bexmarilimab) - Cancer | Phase 1 / Phase 2 | Completed | Faron Pharmaceuticals Ltd | 216 | 2018-12-03 | 2025-04-02 |
Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Melanoma (1) · Myelodysplastic Syndromes (1) · Sarcoma (1)
Faron Pharmaceuticals Ltd (4) · Institute of Cancer Research, United Kingdom (1) · MedSIR (1) · The University of Texas Health Science Center at San Antonio (1)
Finland (4) · United Kingdom (4) · United States (4) · France (2) · Spain (2) · Czechia (1) · Italy (1) · Netherlands (1) · Poland (1)
Dr Anna Minchom, MB BCh, FRCP, MD (Res) (1) · Mika Kontro, MD, PhD (1) · Petri Bono, MD, PhD (1) · Supreet Kaur, MD (1)
PMID 34078651, PMID 35500016, PMID 38056464, PMID 40369178, PMID 40449509
2018 (1), 2025 (1)